All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
FDA grants Orphan Drug Designation to cerdulatinib for the treatment of peripheral T-cell lymphoma
Bookmark this article
On 25 September 2018, the US Food and Drug Administration (FDA) granted Orphan Drug Designation to cerdulatinib, an oral Syk/JAK inhibitor, for the treatment of peripheral T-cell lymphoma (PTCL).
SYK is a key regulator of BCR signaling and it is also expressed in PTCL. Preclinical studies suggest that SYK may be an oncogenic driver for PTCL. Cerdulatinib is a selective and potent inhibitor of SYK, JAK1, JAK3, and TYK2.
At present, cerdulatinib is being evaluated in an ongoing phase IIb study (NCT01994382), which is assessing the efficacy and safety of cerdulatinib in patients with relapsed or refractory B- and T-cell lymphoma. Interim data presented at the 23rd Congress of the European Hematology Association (EHA) demonstrated that cerdulatinib exhibited broad clinical activity and was well tolerated. Seven of the 20 patients in the PTCL cohort achieved a complete response at the time of presentation.
- Portola Pharmaceuticals: Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib, an Oral Syk/JAK Inhibitor for the Treatment of Peripheral T-Cell Lymphoma. 2018 Sep 25. https://globenewswire.com/news-release/2018/09/25/1576083/0/en/Portola-Pharmaceuticals-Receives-FDA-Orphan-Drug-Designation-for-Cerdulatinib-an-Oral-Syk-JAK-Inhibitor-for-the-Treatment-of-Peripheral-T-Cell-Lymphoma.html [Accessed 2018 Oct 09].
- Hamlin P. A. et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2a study in patients with relapsed/refractory B- and T-cell non- Hodgkin lymphoma (NHL). Abstract #PF437 23rd Congress of the European Hematology Association (EHA).
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youNewsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox